Skinny labels are back in focus at the White House. On September 9, 2021, the U.S. Department of Health and Human Services submitted its much-anticipated report to the White House Competition Counsel regarding a...more
10/11/2021
/ Biosimilars ,
Competition ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Infringement ,
Labeling ,
Patents ,
Pharmaceutical Industry ,
Prescription Drugs ,
Teva Pharmaceuticals